此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Sucrosomial与静脉注射铁剂治疗术前贫血 (RSIVI)

2026年10月1日 更新者:Michael Eaton、University of Rochester

Sucrosomial铁剂与静脉注射铁剂治疗术前贫血的随机试验 (RSIVI)

50 patients with anemia scheduled for heart surgery or procedures will be randomized to receive either oral sucrosomial iron or standard-of-care intravenous iron before surgery to see if the oral iron is as effective as intravenous iron in increasing the red blood cell count.

研究概览

详细说明

Participants will be randomly assigned in a 1 to 1 ratio to one of two treatment groups. One group will receive intravenous (IV) iron, and the other group will receive oral sucrosomial iron.

Participants assigned to the IV iron group will receive two infusions at the University of Rochester Medical Center Center for Perioperative Medicine. Intravenous iron will be administered through a small plastic tube placed into a vein. Saline may be used to maintain the IV line as needed.

Participants assigned to the oral sucrosomial iron group will receive capsules to take at home until the date of surgery, with a dosage of two capsules per day.

All other aspects of perioperative care will follow standard practice. A blood sample for complete blood count and iron studies will be obtained on the day of surgery. This is typically collected when the IV is placed, so an additional needle stick is usually not required.

Randomization applies only to the two treatment arms (intravenous iron and oral sucrosomial iron). The third arm is a non randomized observational cohort for data collection only.

研究类型

介入性

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • Rochester、New York、美国、14642
        • University of Rochester

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age ≥18 years
  • Scheduled for elective cardiac surgical procedures, including:
  • Coronary artery bypass graft surgery (CABG)
  • Valve procedures
  • Aortic root procedures
  • Transcatheter aortic valve implantation (TAVI)
  • Hemoglobin <12 g/dL and ≥10 g/dL on a complete blood count obtained at the Center for Perioperative Medicine pre operative visit
  • Evidence of iron deficiency
  • Able to provide informed consent
  • Able to understand spoken and written English

Exclusion Criteria:

  • Scheduled for cardiac surgery requiring deep hypothermia or circulatory arrest
  • Undergoing heart transplantation or ventricular assist device placement
  • Lacking capacity to provide informed consent or unable to understand spoken and written English
  • Baseline hemoglobin >12 g/dL or <10 g/dL
  • Use of anticoagulant medications within 5 days of the Center for Perioperative Medicine visit, or planned initiation of anticoagulant therapy before surgery
  • History of hemoglobinopathy
  • History of hematologic malignancy
  • Bone marrow suppression from non nutritional causes
  • Vitamin B12 or folate deficiency
  • Known liver disease
  • Known kidney disease
  • Normal serum iron studies at baseline

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
有源比较器:intravenous (IV) iron

If a participant is to receive IV iron, they will be scheduled to have two infusions, at the URMC Center for Perioperative Medicine (CPM). They will receive the iron through an IV, which is a small plastic tube inserted into a vein in the arm using a needle. This may require that saline water be inserted into the tube to keep the tube from clogging.

2 infusions of intravenous iron (ferumoxytol)

实验性的:Sucrosomial Iron

If a participant is to receive oral iron capsules, they will be provided with enough capsules to last until the date of surgery and will take 2 capsules every day.

blood draw on the day of surgery to check hemoglobin and red blood cell count and iron studies

无干预:3rd arm is for data collection only

In addition, 25 patients refusing randomization, but accepting data collection, will be treated as per the standard of care, but will have data collected as for the randomized groups with the exception of no CBC or iron studies will be performed on the day of surgery unless as part of routine care unrelated to study participation.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in hemoglobin from baseline to day of surgery or procedure
大体时间:From the pre operative visit to the day of surgery or procedure, up to approximately eight weeks

Change in hemoglobin in grams per deciliter from the baseline pre operative complete blood count to the complete blood count obtained on the day of surgery or procedure. Change will be calculated as hemoglobin on the day of surgery minus baseline hemoglobin.

From the pre operative visit to the day of surgery or procedure, up to approximately eight weeks

次要结果测量

结果测量
措施说明
大体时间
Treatment compliance
大体时间:From the pre operative visit to the day of surgery or procedure, up to approximately eight weeks

Proportion of participants who complete the assigned iron treatment. Compliance is defined as receiving both infusions in the intravenous arm and taking the prescribed capsules in the oral arm, based on pill counts and participant reporting.

From the pre operative visit to the day of surgery or procedure, up to approximately eight weeks
Proportion of participants receiving any blood transfusion
大体时间:From the end of surgery or procedure through thirty days post procedure

Number of participants who receive at least one transfusion of blood products after surgery or procedure

From the end of surgery or procedure through thirty days post procedure
Change in iron study values from baseline to the day of surgery or procedure
大体时间:From the pre operative visit to the day of surgery or procedure, up to approximately eight weeks

Change in serum iron, ferritin, and transferrin saturation between baseline and day of surgery

From the pre operative visit to the day of surgery or procedure, up to approximately eight weeks
Post operative complications
大体时间:From the end of surgery or procedure through thirty days

Number of participants who experience any of the following within thirty days: acute kidney injury, stroke, infection requiring antimicrobial therapy, or death.

From the end of surgery or procedure through thirty days
Length of intensive care unit stay
大体时间:30 days after hospital discharge

Duration of ICU stay in days, from ICU admission after surgery or procedure until ICU discharge.

30 days after hospital discharge
Length of hospital stay
大体时间:30 days after hospital discharge

Duration of hospitalization in days, from admission for surgery or procedure until discharge

30 days after hospital discharge

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Michael P Eaton, MD、University of Rochester

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2027年6月30日

研究注册日期

首次提交

2025年11月24日

首先提交符合 QC 标准的

2025年12月11日

首次发布 (实际的)

2025年12月17日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2025年12月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅